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Abstract: Agonist activation of G protein-coupled receptors promotes sequential interaction of the
receptor with heterotrimeric G proteins, G protein-coupled receptor kinases (GRKs), and arrestins.
GRKs play a central role in mediating the switch from G protein to arrestin interaction and thereby
control processes such as receptor desensitization and trafficking and arrestin-mediated signaling. In
this review, I provide a historical perspective on some of the early studies that identified the family of
GRKs with a primary focus on the non-visual GRKs. These studies included identification, purifica-
tion, and cloning of the β-adrenergic receptor kinase in the mid- to late-1980s and subsequent cloning
and characterization of additional members of the GRK family. This helped to lay the groundwork
for ensuing work focused on understanding the structure and function of these important enzymes.
Keywords: arrestins; GPCR; GRK; phosphorylation; signaling
1. Introduction
G protein-coupled receptors (GPCRs) are the largest family of membrane-localized
proteins in mammals and function to enable cells to transmit extracellular stimuli such as
hormones, chemokines, ions, peptides, and sensory stimuli into intracellular functional
changes [1]. GPCRs primarily mediate their effects via the ability to interact in an activation-
dependent manner with three protein families: heterotrimeric G proteins, GPCR kinases
(GRKs), and arrestins. Initial work by the Rodbell and Gilman laboratories led to the
discovery of the heterotrimeric G proteins [2], whereas studies in retinal rod cells by several
groups led to the initial discovery of GRKs and arrestins. Subsequent work in the Lefkowitz
and Caron laboratories led to the initial identification of non-visual GRKs and arrestins. In
this review, I provide a historical overview of the initial discovery and characterization of
the GRKs largely from my own personal perspective. This was the primary focus of my
research in the Lefkowitz lab in the 1980s as well as a major focus of studies in my own
laboratory starting in 1989.
2. Discovery of Rhodopsin Kinase
The history of the GRKs began in the 1970s with research in the visual system. Initial
work by three groups demonstrated light-dependent phosphorylation of rhodopsin in rod
membranes [3–5], whereas additional studies were able to extract a kinase from rod mem-
branes that could phosphorylate photobleached rhodopsin [6]. The kinase was initially
named opsin kinase [6] and later rhodopsin kinase (now called GRK1), and it was subse-
quently purified and found to specifically phosphorylate light-activated rhodopsin [7,8].
The latter purification involved salt extraction of rod outer segments followed by sequential
fractionation on DE-cellulose 52 and hydroxyapatite resulting in a 1000-fold overall purifi-
cation and recovery of 50 µg of purified kinase from 400 bovine retinas [8]. Properties of
rhodopsin kinase include a molecular weight of 67–70 kDa, specificity for phosphorylation
of photoactivated rhodopsin, and insensitivity to various second messengers, including
cAMP, cGMP, and inositol trisphosphate.
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3. Discovery of the β-Adrenergic Receptor Kinase (βARK)
Studies in the Lefkowitz laboratory during the late 1970s and early 1980s were focused
on understanding the mechanisms involved in the loss of responsiveness of β-adrenergic
receptor (βAR) signaling following prolonged stimulation with a β-agonist, a process
that was termed desensitization or tachyphylaxis. These studies revealed that the βAR
underwent a mobility shift on gel electrophoresis following agonist treatment of cells and
demonstrated that this shift was due to receptor phosphorylation [9,10]. Additional studies
established that at least some of this phosphorylation was due to the cAMP-dependent
protein kinase (PKA) [11]. Intertwined with our understanding of this process were studies
focused on purification of the β-adrenergic receptor, initially from frog [12] and turkey [13]
erythrocytes followed by mammalian tissues such as hamster, rat, and guinea pig lung [14].
The purified hamster β2-adrenergic receptor (β2AR) was then fed into three projects: (1)
one to reconstitute the receptor into phospholipid vesicles to determine if the purified
receptor could directly activate the purified stimulatory heterotrimeric G protein (Gs or Ns)
in an agonist-dependent manner [15,16]; (2) one to obtain amino acid sequence to use in
cloning a cDNA for the β2AR [17]; and (3) one to better understand the process of receptor
desensitization. In regard to the desensitization efforts, in vitro studies demonstrated
that PKA could directly phosphorylate the purified β2AR to a stoichiometry of 2 mol
phosphate/mol receptor and that this phosphorylation directly inhibited receptor coupling
to Gs, although only 25% inhibition was observed in these initial studies [18]. Subsequent
studies found that PKA phosphorylation of the receptor inhibited β2AR-Gs coupling by 60%
at physiological concentrations of Mg2+ [19]. Thus, these studies identified a mechanism of
feedback regulation that involved phosphorylation of the β2AR by PKA, the protein kinase
activated by the βAR-signaling pathway. While this feedback regulation of the β2AR by
PKA was termed heterologous or agonist-independent desensitization, one interesting
aspect of the in vitro work was that the β2AR was found to be a better substrate for PKA
in the presence of the agonist [18], suggesting that there may be an agonist-dependent or
homologous component to this feedback regulation. To my knowledge, this aspect of the
regulation has never been further explored.
While a role for PKA phosphorylation of the β2AR was evident from these early
studies, additional efforts revealed that the β2AR could also be phosphorylated in an
agonist-dependent manner in S49 lymphoma cell lines that could not activate PKA either
because they lacked the ability to produce cAMP (cyc− cells) or they lacked the PKA
catalytic subunit (kin− cells) [20]. This observation led to a search for the enzyme that
phosphorylated the β2AR in an agonist-dependent manner and ultimately resulted in the
identification of the β-adrenergic receptor kinase or βARK (now called GRK2) [21]. A
critical aspect of this work was the ability to use the purified β2AR as a substrate, which
facilitated the demonstration that this was an agonist-dependent process. Indeed, the
first successful experiment testing the ability of an S49 kin− cell extract to phosphorylate
the purified receptor revealed that phosphorylation was increased in the presence of the
β-agonist isoproterenol and that the agonist effect was blocked by the addition of the
β-antagonist alprenolol (Figure 1).
βARK had clear similarities with rhodopsin kinase in that both enzymes phosphory-
lated the active form of the receptor. These studies were contiguous with the cloning of a
cDNA for the β2AR and, taken together, raised interesting questions about the similari-
ties between phototransduction through rhodopsin and hormonal signaling through the
β2AR [22]. Indeed, additional studies demonstrated that βARK could phosphorylate light-
activated rhodopsin whereas rhodopsin kinase could phosphorylate the agonist-occupied
β2AR, albeit with each kinase preferring its endogenous substrate [23]. An additional series
of studies suggested that βARK might have broad specificity for GPCRs since activation of
the prostaglandin E1 [24] or somatostatin [25] receptors promoted βARK translocation from
the cytosol to the plasma membrane. Moreover, βARK was also able to directly phosphory-
late purified α2-adrenergic receptors in an agonist-dependent manner [26]. Taken together,
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these early studies suggested that βARK had a broad specificity and likely regulated the
agonist-dependent phosphorylation of many GPCRs.




Figure 1. S49 kin− cell extract phosphorylation of purified β2AR. S49 lymphoma kin− cells were 
lysed, centrifuged, and the supernatant was incubated with MgCl2, radiolabeled ATP, purified 
hamster lung β2AR reconstituted in phospholipid vesicles, and either no ligand (lane 1), 10 μM 
isoproterenol (ISO) (lane 2), or 10 μM ISO plus 20 μM alprenolol (ALP) (lane 3) for 30 min at 30 °C. 
The samples were centrifuged, and the pellets were washed, solubilized, and the β2AR was puri-
fied on a small alprenolol affinity column and then run on SDS-PAGE and exposed to film. 
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tially involved searching for a tissue that had a high level of βARK expression with mini-
mal degradation of the enzyme. Analysis of a number of tissues identified bovine cerebral 
cortex as a good source of the βARK activity (i.e., the ability to phosphorylate purified 
β2AR in an agonist-dependent manner), whereas tissues such as lung, spleen, liver, and 
heart had much lower levels of activity [27]. To purify the enzyme, the tissue was homog-
enized, centrifuged, and an ammonium sulfate cut of the soluble fraction was then purified 
through Ultrogel AcA34, DEAE-Sephacel, CM-Fractogel, and hydroxylapatite columns. 
This resulted in an overall purification of 20,000-fold and recovery of 12 μg of purified 
kinase from 100 g of tissue. Purified βARK was 80 kDa, it phosphorylated the agonist-
occupied β2AR with a Km of 0.25 μM, and it had many properties similar to rhodopsin 
kinase. 
Figure 1. S49 kin− cell extract phosphorylation of purified β2AR. S49 lymphoma kin− cells were
lysed, centrifuged, and the supernatant was incubated with MgCl2, radiolabeled ATP, purified
hamster lung β2AR reconstituted in phospholipid vesicles, and either no ligand (lane 1), 10 µM
isoproterenol (ISO) (lane 2), or 10 µM ISO plus 20 µM alprenolol (ALP) (lane 3) for 30 min at 30 ◦C.
The samples were centrifuged, and the pellets were washed, solubilized, and the β2AR was purified
on a small alprenolol affinity column and then run on SDS-PAGE and exposed to film.
The next step in this work involved developing strategies to purify βARK. This
initially involved searching for a tissue that had a high level of βARK expression with
minimal degradation of the enzyme. Analysis of a number of tissues identified bovine
cerebral cortex as a good source of the βARK activity (i.e., the ability to phosphorylate
purified β2AR in a agonist-dependent manner), whereas tissues such as lung, spleen,
liver, and heart had much lower levels of ctivity [27]. T urif th enzyme, the tissue was
homogenized, c ntrifuged, and an ammonium sulfate c t of th soluble fraction wa th n
purified through Ultrogel AcA34, DEAE-Sephacel, CM-Fract gel, and hydroxylapatite
columns. This resulted in an overall purification of 20,000-fold and recovery of 12 µg
of purified kinase from 100 g of tissue. Purified βARK was 80 kDa, it phosphorylated
the agonist-occupied β2AR with a Km of 0.25 µM, and it had many properties similar to
rhodopsin kinase.
Once βARK was purified, the next major goal was to clone a cDNA that encoded the
protein. While we were able to purify βARK in adequate quantities to obtain amino acid
sequence from cyanogen bromide-derived peptides, the subsequent cloning turned out to
be an arduous process since all of the commercial cDNA libraries that were screened turned
up nothing useful—always some positive clones on screening but never any sequences
that matched the sequence of the kinase. So, what was wrong? Was it the amino acid
seque ce obtai ed from the purified βARK preparations? Maybe, b t three different βARK
preparations yielded consi tent results, so we were confid t in the am no acid equences
we wer using to generate the radiolabeled oligonucleotides for screeni g (Figure 2A). Was
it the cDNA libraries we were using? This certainly seemed to be a possibility since the
libraries were mainly commercially obtained, and we were searching for something of low
abundance. I attempted to address this issue by making my own cDNA library, but this
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again yielded nothing useful. We then turned to Dr. Richard Dixon at Merck Sharp and
Dohme Research Laboratories for help since he had played a major role in the cloning of
the β2AR [17]. Following a phone call from Bob Lefkowitz, Dr. Dixon provided us with
a bovine brain cDNA library that he had personally created. The library was screened in
February 1989, and we knew that we had bona fide βARK clones that hybridized with
multiple probes within 10 days (Figure 2B). I had been screening cDNA libraries for two
years at that point, so the level of excitement with the results is hard to describe but certainly
in my top 10 list. Several overlapping clones were quickly sequenced and revealed an open
reading frame of 2067 bp encoding a 689 amino acid protein [28]. Evidence supporting that
the clone encoded βARK included the demonstration that expression in COS-7 cells yielded
a protein that could phosphorylate the β2AR in an agonist-dependent manner. Moreover,
a Southern blot of Hind III- or Sac I-digested bovine genomic DNA identified several
low-stringency hybridizing bands, suggesting the presence of βARK-related genes [28].
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4. The GRK Family
Once βARK was cloned, the next major goal was to identify additional members of
the family. βARK2 (now called GRK3) was the next member cloned and resulted from
low-stringency hybridization studies using the βARK cDNA to probe a bovine brain cDNA
library [29]. βARK2 was 688 amino acids and had 85% amino acid identity to βARK,
with the kinase catalytic domain being 95% identical (Table 1). βARK2 had lower activity
against the β2AR and rhodopsin as substrates and tended to be expressed at a lower level
in most tissues compared to βARK.
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Table 1. Amino acid homology of human G protein-coupled receptor kinases (GRKs).
GRK1 GRK2 GRK3 GRK4 GRK5 GRK6 GRK7
GRK1 100 52 52 66 69 68 66
GRK2 33.4 100 92 54 54 55 53
GRK3 33.5 84.0 100 53 53 55 53
GRK4 47.7 36.4 36.5 100 81 79 65
GRK5 47.8 37.2 37.1 68.0 100 84 65
GRK6 48.2 38.7 38.9 66.6 72.3 100 66
GRK7 47.6 31.2 32.2 47.9 45.9 46.5 100
Percent amino acid identity (in black) or similarity (in red) of human GRKs. Pairwise comparisons
were conducted using sequences from human GRK1 (563 amino acids, Q15835 from UniProtKB),
GRK2 (689 amino acids, P25098), GRK3 (688 amino acids, P35626), GRK4α (578 amino acids, P32298),
GRK5 (590 amino acids, P34947), GRK6A (576 amino acids, P43250), and GRK7 (553 amino acids,
Q8WTQ7) using BlastP at blast.ncbi.nlm.nih.gov.
Rhodopsin kinase was the next GRK to be cloned via collaborative efforts between the
Palczewski and Lefkowitz laboratories. This involved obtaining amino acid sequences of
the purified protein to generate oligonucleotide probes that were used to screen a bovine
retina cDNA library. This yielded clones encoding a 561 amino acid protein with 33.5%
overall identity to βARK [30] (Table 1). Interestingly, the C-terminal domain of rhodopsin
kinase was much shorter than that of βARK and ended with a CAAX motif suggesting that
the protein may be prenylated. Indeed, subsequent studies showed that rhodopsin kinase
is farnesylated and that this modification is important for full kinase activity [31]. The
fourth member of the family to be cloned was called IT11 (interesting transcript 11, now
called GRK4) and was fortuitously cloned as a result of its location near the Huntington’s
disease locus [32]. The original IT11 clone encoded a 500 amino acid protein and had
48% overall identity to rhodopsin kinase and 36% to βARK (Table 1). A subsequent study
showed that there are four splice variants of GRK4, that expression was primarily limited
to the testes, and that the protein was palmitoylated [33].
Efforts from a number of laboratories ultimately led to the cloning and characterization
of GRK5 and GRK6. GRK5 was initially cloned by the Benovic laboratory using degenerate
oligonucleotides derived from unique GRK regions to amplify human heart cDNA using
the polymerase chain reaction (PCR) [34]. GRK5 was 590 amino acids and had the highest
amino acid homology with IT11, followed by rhodopsin kinase and βARK (Table 1).
GRK5 expression was highest in heart and lung and lowest in brain, liver, and kidney.
GRK5 was also cloned from a taste cell cDNA library [35]. It is worth noting that while
the first two members of the GRK family were named after their substrate (rhodopsin
or β2AR), the initial study identifying GRK5 recommended that the nomenclature be
standardized [34]. The recommendation in the originally submitted manuscript was to
use the GPRK nomenclature that had been used for two Drosophila members of the G
protein-coupled receptor kinase family that had been identified, GPRK1 and GPRK2 [36].
However, the reviewer of the manuscript recommended the use of GRK instead of GPRK,
so this ultimately led to the current naming of the family. The kinases were then named
based on their order of discovery with GRK1 for rhodopsin kinase, GRK2 for βARK, GRK3
for βARK2, and GRK4 for IT11.
Additional efforts in the Benovic laboratory used the GRK2 and GRK3 cDNAs to
screen a human heart cDNA library by low-stringency hybridization. This yielded the sixth
member of the family (GRK6), a 576 amino acid protein with the highest identity to GRK5
and GRK4 [37]. GRK6 had an expression pattern similar to GRK2 with the highest levels
in brain and skeletal muscle > heart, lung and kidney > liver. Initial functional studies
suggested that GRK6 activity was significantly lower than GRK2, at least using rhodopsin
and the β2AR as substrates. GRK6 was also cloned from cDNA prepared from human
neutrophils using PCR amplification [38], although this clone appears to be a splice variant
since it lacks the region that encodes the N-terminal 32 amino acids found in the GRK6
cloned from the human heart cDNA library. The final mammalian member of the GRK
family to be cloned was GRK7 [39,40]. GRK7 cloned from mammalian species by RT-PCR
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was 548 amino acids with expression in cones [39], whereas cloning from medaka yielded
a 563 amino acid protein containing a putative C-terminal site for geranylgeranylation [40].
GRK7 is most homologous to GRK1, GRK4, GRK5, and GRK6 (all 46–48% identity) with
lower homology to GRK2 and GRK3 (31–32%).
5. Role of GRKs in Desensitization
During the course of the early work on GRKs, another protein that contributes to
the regulation of GPCR function was identified. This protein was initially described as
a 48 kDa protein that interacted with photoreceptor membranes in a light-dependent
manner [41]. This 48 kDa protein was found to be identical to another rod cell protein
called S-antigen and was shown to bind to phosphorylated rhodopsin and inhibit rod cGMP
phosphodiesterase activity [42–44]. The protein was ultimately named arrestin based on
its ability to bind to light-activated rhodopsin and arrest or turn-off phototransduction. A
key feature of arrestin was its ability to bind to light-activated rhodopsin that had been
phosphorylated by rhodopsin kinase [44]. While similarities between the regulation of
phototransduction and hormonal signaling were starting to be established in the mid-
1980s [21,22], these similarities were extended by efforts supporting a role for an arrestin in
desensitizing β2AR signaling [45]. These studies found that crude βARK preparations had
the ability to phosphorylate purified β2AR and effectively inhibit receptor interaction with
purified Gs. β2AR phosphorylation by more highly purified βARK preparations, however,
had a modest effect on receptor-Gs coupling. This suggested the loss of a desensitization-
factor during the βARK purification, and we were able to demonstrate that purified visual
arrestin could inhibit β2AR interaction with Gs in a phosphorylation-dependent manner,
albeit at very high stoichiometries [45]. This suggested that the desensitization factor that
was lost during the βARK purification was a non-visual arrestin, although our attempts to
isolate this factor were unsuccessful. Nevertheless, these efforts ultimately led to the cloning
of a non-visual arrestin termed β-arrestin (now called β-arrestin-1 or arrestin-2) that could
specifically bind to βARK-phosphorylated β2AR and inhibit receptor interaction with
Gs [46]. Thus, these early studies found that GRKs play a central role in promoting arrestin
binding to agonist-activated GPCRs and function to turn off receptor interaction with
heterotrimeric G proteins, a process termed agonist-specific or homologous desensitization.
We now know that there are four arrestins, two visual and two non-visual, that coordinate
with GRKs to desensitize GPCR signaling through G proteins [47,48]. Moreover, the two
non-visual β-arrestins also play important roles in GPCR trafficking [49,50] as well as
arrestin-mediated signaling [51,52], although mechanistic details of these processes remain
to be fully defined.
6. Summary
While the studies described above highlight some of the initial work identifying the
GRK family, we now know much more about the role of GRKs in regulating GPCR function,
a topic that has been extensively reviewed over the years [47,48,53–58]. What is left to
do? We know a lot about GRKs and GRK activation from structural studies [59–66] and
have some mechanistic insight on GRK-GPCR interaction [67,68]. For example, GRK5
binding to the β2AR promotes disruption of an ionic lock between the catalytic and
regulator of G protein signaling homology (RH) domains that normally helps to maintain
the kinase in a basal state [67], whereas a similar conformational change is observed when
calmodulin binds to GRK5, leading to disruption of catalytic-RH domain interaction and
kinase activation [69]. However, we still do not know what determines the specificity of
GRK-GPCR interaction. We know that GRKs are activated by binding to GPCRs [70,71],
but we do not know if this activation solely enhances GPCR phosphorylation or whether
it also enhances the phosphorylation of additional substrates. We know that GRKs can
phosphorylate many proteins other than GPCRs [55–57,72], but there have been no broad-
based proteomic studies to broadly define the GRK phospho-proteome. GRKs have also
been implicated in the barcode hypothesis that proposes that different sites of GPCR
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phosphorylation will induce distinct conformations and functions of bound arrestin [73,74],
but we know little about the link between specific sites of phosphorylation, the GRK and
arrestin involved, and the functional consequences. We also know that GRKs are potential
targets in the treatment of several diseases, including cardiovascular disease, metabolic
and neurological disorders, and cancer [55–57], but much remains to be learned about the
best strategies to target specific GRKs and the side effects that might occur in doing so. We
have learned much about GRKs since their initial discovery some 40 plus years ago, but
there seems to be plenty left to do.
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